New Center for Research of Primary Sclerosing Cholangitis Created in Boston
Fall is a GREAT time of year to visit Boston--and you feel AWESOME about helping to raise funds for PI! [Source: pixabay.com]

New Center for Research of Primary Sclerosing Cholangitis Created in Boston

Copyscape score: 2% Brigham and Women's is launching the nation's first ever center to conduct research on primary sclerosing cholangitis, a rare liver disease that affects about 30,000 people in…

Continue Reading New Center for Research of Primary Sclerosing Cholangitis Created in Boston
Regeneron’s REGN-EB3 Proves Superior as Treatment for Ebola in Clinical Trial
source: pixabay.com

Regeneron’s REGN-EB3 Proves Superior as Treatment for Ebola in Clinical Trial

According to a story from PR Newswire, the biotechnology company Regeneron Pharmaceuticals, Inc., recently announced the release of data from a clinical trial comparing four experimental treatments for Ebola virus…

Continue Reading Regeneron’s REGN-EB3 Proves Superior as Treatment for Ebola in Clinical Trial
A Potential Treatment for Cholangiocarcinoma is Accepted for Priority Review
source: pixabay.com

A Potential Treatment for Cholangiocarcinoma is Accepted for Priority Review

According to a story from BioPortfolio, the biopharmaceutical company Incyte Corporation has recently announced that the company's New Drug Application (NDA) was recently accepted by the US Food and Drug…

Continue Reading A Potential Treatment for Cholangiocarcinoma is Accepted for Priority Review
Study: Idursulfase Therapy is a Safe Treatment for Hunter Syndrome (MPS II)
Pexels / Pixabay

Study: Idursulfase Therapy is a Safe Treatment for Hunter Syndrome (MPS II)

  A recent meta-analyses of clinical studies and case reports that examined the safety of idursulfase therapy, which is an enzyme therapy, has shown that this form of treatment is…

Continue Reading Study: Idursulfase Therapy is a Safe Treatment for Hunter Syndrome (MPS II)
Close Menu